FNP-223, previously known as ASN90, is a reversible and substrate-competitive O-GlcNAcase enzyme inhibitor. The oral investigational drug is expected to rapidly increase O-GlcNAcylated tau proteins, ...

“When she would fall in public, people just assumed she was drunk,” said Glenn. “One time she fell backwards on the steps and ...

So, let’s talk about faith. I’m no rabbi or scholar, and I’m not trying to write a religious work. But putting my thoughts ...

In The Salt Path, Raynor Winn writes that she and her husband lost their home after investing a “substantial sum” into a ...

Progressive supranuclear palsy manifests in patients with symptoms such as difficulty speaking, imbalance, changes in gait, cognitive problems 2-4.

Commercial real estate player and former Kislak President Jeffrey Wiener died July 9 after a long battle with progressive ...

Researchers from Asan Medical Center, one of South Korea's largest hospitals, have developed a generative AI model that can ...

Epidemiology & Pathogenesis Progressive supranuclear palsy is the most frequent parkinsonian disorder after PD. Its prevalence increases with age. [62] The average annual incidence rate for PSP ...

Progressive Supranuclear Palsy and Corticobasal Degeneration: Similarities and Differences Pratap Chand, MD, DM, FRCP; Irene Litvan, MD Disclosures Future Neurology. 2008;3 (3):299-307. 0 ...

TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.

Raynor Winn's 2018 memoir The Salt Path is billed as a "true story" based on her and her husband Moth's 630-mile trek along ...

When progressive supranuclear palsy (PSP), a rare neurodegenerative disorder, started affecting his movement, his wife and ...